WO2021108855A1 - Compositions de flavonoïde neurologiquements actives et leurs méthodes d'utilisation - Google Patents

Compositions de flavonoïde neurologiquements actives et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2021108855A1
WO2021108855A1 PCT/AU2020/051313 AU2020051313W WO2021108855A1 WO 2021108855 A1 WO2021108855 A1 WO 2021108855A1 AU 2020051313 W AU2020051313 W AU 2020051313W WO 2021108855 A1 WO2021108855 A1 WO 2021108855A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
flavonoid
human
cell
modulation
Prior art date
Application number
PCT/AU2020/051313
Other languages
English (en)
Inventor
Alistair Cumming
Original Assignee
Gretals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904626A external-priority patent/AU2019904626A0/en
Application filed by Gretals Australia Pty Ltd filed Critical Gretals Australia Pty Ltd
Priority to AU2020395610A priority Critical patent/AU2020395610A1/en
Publication of WO2021108855A1 publication Critical patent/WO2021108855A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/055—Organic compounds containing sulfur as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/56—Flavouring or bittering agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/68—Acidifying substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/122—Coated, filled, multilayered or hollow ready-to-eat cereals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Definitions

  • Nicotine is used extensively for its anxiolytic effects, normally by smoking tobacco or inhalation via electronic cigarettes. Nicotine agonises the nicotinic acetylcholine receptor, resulting in a number of downstream effects including an increase in activity of dopaminergic neurons in the midbrain reward system, as well as the decreased expression of monoamine oxidase in the brain. Nicotine is reported to improve concentration and the ability to perform complex tasks quickly. Nicotine is addictive and dependence forming to a much greater extent than many other stimulants and relaxants.
  • the organic acid is of the type naturally synthesised in an animal cell, although is not necessarily obtained from an animal cell for use in the composition.
  • the flavone and/or the organic acid (where present) is/are capable of effecting a cell, a tissue, a structure, or an organ of the human central nervous system in any one or more of the following parameters: modulation of inflammation, modulation of neural cell membrane permeability, inhibiting the receptor for advanced glycation end products (RAGE), modulating mitochondrion-mediated apoptosis, reduction in reactive oxygen species, modulation of neurotransmission, potentiation of the striatum/hippocampus, membrane stabilization, modulation of neural cell volume, and inhibition of glutamate -mediate neurotoxicity.
  • modulation of inflammation modulation of neural cell membrane permeability
  • RAGE receptor for advanced glycation end products
  • mitochondrion-mediated apoptosis modulating mitochondrion-mediated apoptosis
  • reduction in reactive oxygen species modulation of neurotransmission
  • potentiation of the striatum/hippocampus potentiation of the striatum/hippocampus
  • compositions may take the form, for example, of solid preparations including tablets, capsules, caplets, dragees, lozenges, granules, powders, pellets, beads and cachets; and liquid preparations including elixirs, symps, suspensions, sprays, emulsions, lotions, creams and solutions.
  • solid preparations including tablets, capsules, caplets, dragees, lozenges, granules, powders, pellets, beads and cachets
  • liquid preparations including elixirs, symps, suspensions, sprays, emulsions, lotions, creams and solutions.
  • the active flavonoid and organic acid may be mixed with one or more pharmaceutically acceptable carriers, such as dicalcium phosphate, and/or any of the following: diluents, fillers or extenders, such as starches, lactose, sucrose, glucose, dextrates, mannitol, microcrystalline cellulose and/or silicic acid; binders, such as, for example, hydroxypropylcellulose, hypromellose, hydroxypropyl methylcellulose, polyglycol such as polyethylene glycol, carboxymethylcellulose, gelatine, polyvinyl pyrrolidone’s, polyvinyl acetate, sucrose and/or acacia; disintegrating agents, such as starch, for example, potato or tapioca starch, starch derivatives such as sodium starch glycolate, crospolyvinylpyrollidone, calcium carbonate, croscarmellose sodium, alginic acid, silicone dioxide, and certain pharmaceutically acceptable carriers, such as dicalcium phosphate,
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions for oral ingestion. Liquid preparations can also be formulated in aqueous solution.
  • the flavonoid and the organic acid may be mixed with one or more food acceptable or pharmaceutically acceptable carriers and/or excipients and/or diluents, such as water and/or any of the following: solvent such as propylene glycol, alcohol; humectant such as glycerol; sweeteners such as liquid glucose, com symp and sucrose; artificial sweeteners such as aspartame, stevia and sucralose; preservatives such as benzoates and parabens; viscosity modifiers/thickeners such as gums and alginates; buffering agents; flavouring agents and colouring agents.
  • solvent such as propylene glycol, alcohol
  • humectant such as glycerol
  • sweeteners such as liquid glucose, com s
  • the composition is ingested at least daily or weekly by the subject.
  • a single ingestion will provide a positive neurological effect. It is contemplated that regular ingestion will lead to long term improvement in neurological function, and possibly even positive remodelling of neurological function. For some subjects, only a transient effect is required (for example when studying or prior to an examination) in which case an isolated ingestion may be sufficient.
  • a first bread loaf product is prepared according to industry standard methods and using industry standard ingredients, except that pincocembrin (in purified powdered form) is well mixed with flour at a rate of 0.1% to 10% (w/w) before combining with other ingredients.
  • a first breakfast cereal flake breakfast product is prepared according to industry standard methods and using industry standard ingredients, except that a pincocembrin solution is evenly sprayed onto the exterior surfaces of the flakes while being continuously tossed in a rotating bin. Air is blown through the coated flakes to evaporate solvent from the pinocembrin composition to leave a pinocembrin coating.
  • the pinocembrin solution comprises also a sugar or other substance that will positively adhere to the flake surface thereby trapping the pinocembrin to the flake.
  • the pinocembrin solution is prepared to provide a 0.1% to 10% (w/w of flakes).
  • a second breakfast cereal flake breakfast product is prepared according to industry standard methods and using industry standard ingredients, except that a pincocembrin and taurine solution is evenly sprayed onto the exterior surfaces of the flakes while being continuously tossed in a rotating bin. Air is blown through the coated flakes to evaporate solvent from the pinocembrin and taurine solution to leave a pinocembrin/taurine coating. [100].
  • the pinocembrin and taurine solution comprises also a sugar or other substance that will positively adhere to the flake surface thereby trapping the pinocembrin to the flake.
  • the pinocembrin and taurine solution is prepared to provide a 0.1% to 10% (w/w of flakes).
  • EXAMPLE 5 Administration of composition and effects on mood and cognitive function.
  • Control #1 Composition as for Example 1 , except devoid of pinocembrin
  • Control #2 Composition as for Example 1 , except devoid of taurine. [106].
  • Control #3 Composition as for Example 1, except devoid of taurine and pinocembrin
  • a first test composition 250 ml is prepared so as to mimic pinocembrin-fortified Red BullTM energy drink (as per the composition of Example 3 herein).
  • a range of pinocembrin concentrations may be used, such as 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 15.0 or 20.0 g/lOOOml.
  • a range of taurine concentrations may be used, such as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 15.0 or 20.0 g/lOOOml.
  • Control compositions are prepared as for the test composition, except for a first control composition is devoid of taurine, a second control composition is devoid of pinocembrin and a third control composition is devoid of both pinocembrin and taurine.
  • a second test composition is prepared using a Red BullTM energy drink obtained through a normal retail outlet to which Pinocembrin is added to a final concentration of 4 g/1000 ml.
  • a range of pinocembrin concentrations may be used, such as 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 15.0 or 20.0 g/lOOOml.
  • regular Red BullTM energy drink obtained through a normal retail outlet is used.
  • compositions for the first experiment and the second experiment as detailed above are used in separate experiments, and each experiment having a different set of subjects.
  • CogTrack system an online set of nine cognitive tests accessible at the URL www.wesnes.com. Before each test, all required task resources are downloaded within the web browser, to ensure the rates of stimuli presentation and assessment of speed and accuracy are managed on the local computer. At completion of each task data are uploaded to the administering server. This procedure negates any fluctuation in Internet connection speeds from affected the outcome of each test. [136]. Instructions for a task are presented to the subject on the computer screen, with the subject initiating the test by pressing a designated key on the computer keyboard. Task stimuli are presented on the same screen. Responses within each task are made using the keyboard. There are nine tasks in total, each of which is described below and in the order administered:
  • Word recall a list of fifteen words is shown on the screen, at the rate of one word every two seconds. The subject is then allowed one minute to type all recalled words using the keyboard. Words correctly recalled and any errors are quantitated.
  • Digit vigilance task A computer randomly selects a target digit (1-9) and displays the digit constantly on a side portion of the screen. Digits are shown (one at a time) in the screen centre at a rapid rate. The subject must quickly press a dedicated key as where the two digits match. A total of 450 digits is presented to the subject, with 15 target digits in each block of 150 digits. Correct matches, detection speed and erroneous responses are all recorded.
  • Choice reaction time task This task has two possible stimuli in this task: a right facing arrow or a left-facing version of the arrow, having the word ‘NO’ overlaid. For each of 50 trials, one of the two stimuli is selected randomly by the computer and displayed to the subject in the screen centre, and remains until the subject enters a response. The interval between each trial is randomly varied, and the subject maintains the left and right index fingers resting on the relevant keys and responds as quickly and accurately as possible. The accuracy and speed of each response is recorded.
  • Delayed word recall task The subject is allowed 60 seconds to enter (by keyboard) as many words as can be recalled from an earlier presented list, and in any order. The number of words correctly recalled and the number of erroneous words recalled are recorded. [145].
  • Word recognition task An original list of fifteen words plus fifteen distractor words are shown to the subject consecutively in a random order. For each word the subject indicates if it was from the original list of words (if positive, the right keyboard arrow is pressed, otherwise the left arrow is pressed). Each word remains displayed until the subject responds.
  • Pattern separation task (second stage): The original images and the twenty similar distractor images are presented to the subject sequentially. One-half of the original images are shown before the distractor version, and one-half after. For each image the subject indicates if it was identical to the preceding image (if positive, the right keyboard arrow is pressed, otherwise the left arrow is pressed). Each image remains until the subject responds. The accuracy and speed of the subject’s responses are recorded.
  • the accuracy scores of the tasks are loaded together on one factor, and the speed scores on another factor.
  • the three speed scores are added to give an attentional intensity index.
  • the accuracy scores are combined to give a sustained attention index.
  • the accuracy scores from the working memory and four episodic memory tasks are combined to give a memory capacity index.
  • the speed scores from the numeric working memory, spatial working memory, word recognition and pattern separation tasks are loaded together on a single factor and combined to create a speed of retrieval index.
  • Subjects’ mood and alertness is self-rated by the use of visual analogue scales and questionnaires. [150]. A scale used in caffeine research is exploited. The self-rating captures mood changes and involves seven descriptors, ‘relaxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’, ‘headache’ and ‘overall mood. Each description is followed by a 10 cm line scale which the subject marks according to how he/she feels at the time. A rating of from 0-100 is given.
  • the Profile of Mood States (POMS; McNair) is used, involving a 65-point self- report questionnaire to give six validated factor scores: tension, depression, anger, vigour, fatigue and confusion, plus a total score termed total mood disturbance.
  • the initial study day is set aside to familiarise subjects with the CogTrack tasks. Height and weight measurements are taken to calculate BMI. Over the three following study days, the CogTrack tasks and the three self-rating scales are undertaken. Subjects then ingest all of their allocated treatment drink within five minutes. The same assessment procedures are repeated at 30, 60 and 90 min after ingestion of the drink, except for the Bond-Lader VAS and POMS tests which were repeated only at 90 minutes.
  • Statistical analyses are conducted using a statistical package (SAS). Mixed model repeated measure analyses of variance (ANOVAs) are performed on the change from control data. Each of the following are fixed factors: study drink (three levels), time of testing (three levels), sequence (six levels), and the interaction between study drink and Time of testing, were fitted as fixed factors. Subjects are fitted as a random factor. The compound symmetry covariance structure is used. Degrees of freedom are adjusted using the Kenward-Roger approximation.

Abstract

La présente invention concerne des compositions comprenant (i) un flavonoïde capable de traverser la barrière hémato-encéphalique d'un être humain pour affecter une cellule, un tissu, une structure ou un organe du système nerveux central humain, et (ii) un ou plusieurs nutriments, solvants, ou solutés humainement compatibles, et/ou (iii) un ou plusieurs excipients pharmaceutiquement acceptables. L'invention concerne en outre l'utilisation de ladite composition pour traiter ou prévenir un état associé à une altération d'un ou plusieurs des paramètres suivants : fonction cognitive, résolution de problèmes, vigilance, capacité d'attention, mémoire, concentration et humeur. Un exemple de flavonoïde est le flavanone (2S)-5,7-dihydroxy-2-phényl-2,3-dihydrochromen-4-one d'origine naturelle (pinocembrine). La composition peut éventuellement comprendre un acide organique tel que la taurine.
PCT/AU2020/051313 2019-12-06 2020-12-03 Compositions de flavonoïde neurologiquements actives et leurs méthodes d'utilisation WO2021108855A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020395610A AU2020395610A1 (en) 2019-12-06 2020-12-03 Neurologically active flavonoid compositions and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019904626 2019-12-06
AU2019904626A AU2019904626A0 (en) 2019-12-06 Neurologically active compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
WO2021108855A1 true WO2021108855A1 (fr) 2021-06-10

Family

ID=76221244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2020/051313 WO2021108855A1 (fr) 2019-12-06 2020-12-03 Compositions de flavonoïde neurologiquements actives et leurs méthodes d'utilisation

Country Status (2)

Country Link
AU (1) AU2020395610A1 (fr)
WO (1) WO2021108855A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080021096A1 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
WO2009062374A1 (fr) * 2007-10-15 2009-05-22 Fugui Cui Utilisation pharmaceutique de liquiritigénine pour préparer un médicament destiné au traitement de maladies neurodégénératives
US7771756B1 (en) * 2005-06-16 2010-08-10 Schlesser Jerry L Nutritional supplement to enhance learning, academic, and behavioral functioning
WO2010146577A1 (fr) * 2009-06-18 2010-12-23 Innosense Ltd. Produits comestibles avec effets thermostatiques et cognitifs
WO2011156479A2 (fr) * 2010-06-09 2011-12-15 Emory University Agonistes trkb et leurs procédés d'utilisation
WO2013142370A1 (fr) * 2012-03-19 2013-09-26 Varghese John Inhibiteurs de bace spécifiques de l'app (asbi) et leurs utilisations
EP3037132B1 (fr) * 2014-12-23 2018-10-31 Farma-Derma S.R.L. Sel de zinc et composition de polyphénol

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771756B1 (en) * 2005-06-16 2010-08-10 Schlesser Jerry L Nutritional supplement to enhance learning, academic, and behavioral functioning
US20080021096A1 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
WO2009062374A1 (fr) * 2007-10-15 2009-05-22 Fugui Cui Utilisation pharmaceutique de liquiritigénine pour préparer un médicament destiné au traitement de maladies neurodégénératives
WO2010146577A1 (fr) * 2009-06-18 2010-12-23 Innosense Ltd. Produits comestibles avec effets thermostatiques et cognitifs
WO2011156479A2 (fr) * 2010-06-09 2011-12-15 Emory University Agonistes trkb et leurs procédés d'utilisation
WO2013142370A1 (fr) * 2012-03-19 2013-09-26 Varghese John Inhibiteurs de bace spécifiques de l'app (asbi) et leurs utilisations
EP3037132B1 (fr) * 2014-12-23 2018-10-31 Farma-Derma S.R.L. Sel de zinc et composition de polyphénol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KE WANG, SMITH DANIEL, ZHENG YING: "Electron-driven heterogeneous catalytic synthesis of ammonia: Current states and perspective", CARBON RESOURCES CONVERSION, vol. 1, no. 1, 20 June 2018 (2018-06-20), pages 2 - 31, XP055525523, ISSN: 2588-9133, DOI: 10.1016/j.crcon.2018.06.004 *

Also Published As

Publication number Publication date
AU2020395610A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
US20180104299A1 (en) Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity
CN103520179B (zh) 高血脂症改善剂、贫血改善组合物、尿酸值降低组合物以及饮料食品
JP6335508B2 (ja) 成長ホルモン分泌促進剤
JP2023538664A (ja) ジンセノサイドＲｇ３およびジンセノサイドＲｇ５の組成物ならびに抗腫瘍効果を含むその医薬用途
KR101343819B1 (ko) 11종의 진세노사이드 성분을 유효성분으로 하는 홍삼농축액 분말, 비타민 및 미네랄로 조성된 항스트레스, 항고지혈증 및 항비만용 조성물 및 건강기능식품
JP2009126853A (ja) 治療剤
EP2627199A1 (fr) Extraits de café comme ingrédients de produits alimentaires, de médicaments, de produits cosmétiques, de compléments diététiques, et de produits biologiques
JP2012051940A (ja) ビワ葉抽出物を含有する飲食品及び医薬品
RU2446793C2 (ru) Транквилизатор и функциональный продукт питания
CN107496469A (zh) 睡眠质量改善剂
JP2006083151A (ja) 骨粗鬆症予防、改善用組成物
JP2002293736A (ja) メーラード反応阻害剤およびそれを含有する組成物
TW200814987A (en) Stable and bioavailable compositions of isomers of carotenoids for skin and hair
JP2018516987A (ja) 阿魏茸の水抽出物を有効成分として含有する代謝性疾患の予防及び治療用薬学的組成物又は健康機能性食品
US20100008887A1 (en) Anti-obesity composition containing acacia bark derivative
AU2020395610A1 (en) Neurologically active flavonoid compositions and methods of use thereof
JP2019054791A (ja) 疲労改善用組成物
WO2010048705A1 (fr) Composition pour le maintien des taux de sucre dans le sang comprenant de la cannelle et du ginseng
CN114794478A (zh) 一种能降低血压血脂血糖的组合物及应用
JP7281276B2 (ja) 認知機能改善剤
JP2009096719A (ja) 破骨細胞分化抑制剤
AU2018238285B2 (en) Nutraceutical, dietetic and nutritional composition with antioxidant activity
JP7090864B2 (ja) 組成物
JP2009107952A (ja) 抗骨粗鬆症剤
US20230050805A1 (en) Autonomic nerve regulator and cognitive function improver

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20897066

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020395610

Country of ref document: AU

Date of ref document: 20201203

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20897066

Country of ref document: EP

Kind code of ref document: A1